JBC GenomeOne product landing page

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, D.
Right arrow Articles by Noy, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, D.
Right arrow Articles by Noy, N.

J Biol Chem, Vol. 274, Issue 34, 23695-23698, August 20, 1999

COMMUNICATION
Distinct Roles for Cellular Retinoic Acid-binding Proteins I and II in Regulating Signaling by Retinoic Acid*

Diane Dong, Sarah E. Ruuska, David J. Levinthal, and Noa NoyDagger

From the Cornell University, Division of Nutritional Sciences, Savage Hall, Ithaca, New York 14853

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The pleiotropic effects of retinoic acid (RA) in mammalian cells are mediated by two classes of proteins: the retinoic acid receptors (RAR) and cellular retinoic acid-binding proteins (CRABP-I and CRABP-II). Here we show that expression of CRABP-II, but not CRABP-I, markedly enhanced RAR-mediated transcriptional activation of a reporter gene in COS-7 cells. The equilibrium dissociation constants of complexes of CRABP-I or CRABP-II with RA were found to differ by 2-fold. It is thus unlikely that the distinct effects of the two proteins on transactivation stem from differential ligand-binding affinities. The mechanisms by which RA transfers from the CRABPs to RAR were thus investigated directly. The rate constant for movement of RA from CRABP-II, but not from CRABP-I, to RAR strongly depended on the concentration of the acceptor. The data suggest that transfer of RA from CRABP-I to RAR involves dissociation of the ligand from the binding protein, followed by association with the receptor. In contrast, movement of RA from CRABP-II to the receptor is facilitated by a mechanism that involves direct interactions between CRABP-II and RAR. These findings reveal a striking functional difference between CRABP-I and CRABP-II, and point at a novel mechanism by which the transcriptional activity of RA can be regulated by CRABP-II.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Retinoic acid (RA)1 is an important regulator of cell growth and differentiation both in fetal and in adult tissues. Two classes of proteins are involved in mediating the multiple biological activities of RA. One of these, the retinoic acid receptors (RARs), encompasses ligand-inducible transcription factors that belong to the superfamily of nuclear hormone receptors and that are specifically activated by RA. RARs associate with the retinoid X receptor (RXR) to form RAR-RXR heterodimers, which regulate transcription following binding at the promoter regions of various target genes and activation by their cognate ligands (1). Another class of intra-cellular proteins that bind RA with a high affinity comprises two homologous proteins, cellular RA-binding proteins I and II (CRABP-I and CRABP-II). CRABPs are found in all vertebrates and are highly conserved across species (2). The two CRABP isoforms display different patterns of expression across cells and developmental stages. In the adult, CRABP-I is expressed almost ubiquitously, whereas CRABP-II is only expressed in skin (2), uterus, ovary (3, 4), and in the choroid plexus (5). Both CRABPs are widely expressed in the embryo, although they do not usually co-exist in the same cells (6). The distinct patterns of expression of CRABP-I and II suggest that they serve different functions in the biology of RA, or, perhaps, that they allow for accommodating different requirements for RA in different tissues.

Although the genes for both CRABP isoforms from various species have been cloned and characterized, neither the exact functions of these proteins nor the distinct roles of the two isoforms are completely understood at present. Interestingly, despite the high conservation of CRABPs, mice in which these genes have been disrupted appear essentially normal (7). It is usually proposed that CRABPs serve to solubilize and protect their ligand in cytosol and that they transport RA between different cellular compartments (2). It was suggested, for example, that CRABPs act to deliver their ligand to the nucleus (8). Indeed, it was recently demonstrated that both CRABP isoforms are present not only in cytosol but also in the nuclei of cells (9).

It was also suggested that CRABP-I regulates the metabolic fate of its ligand by directly affecting the activities of RA-metabolizing enzymes. It was reported that the rate of degradation of RA in F9 teratocarcinoma cells increases upon elevation of the expression level of CRABP-I (10). It was shown further that the sensitivity of F9 cells to RA-induced differentiation is inversely correlated to the cellular level of CRABP-I (11). Hence, it is currently believed that CRABP-I moderates cellular response to RA by facilitating catabolism and/or by sequestering RA, rendering it unavailable to nuclear receptors.

Little information is available regarding the specific biological role of CRABP-II. Here, the kinetic patterns that govern the process by which CRABPs deliver their ligand to RAR were examined and correlated with their effects on RAR-mediated transcriptional activation. The observations indicate that CRABP-II, but not CRABP-I, directly interacts with RAR and that these protein-protein interactions markedly facilitate the formation of the RAR·RA complex.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteins-- hRARalpha Lacking the terminal A/B domain (RARalpha Delta AB) was obtained by overexpression in Escherichia coli and purified as described previously (13). This protein displays ligand-binding, DNA-binding, and dimerization properties that are identical to those of the full-length protein (14). Bacterial expression vectors for bCRABP-I and bCRABP-II (in pT7 vector) were provided by David Ong (Vanderbilt University). These proteins were expressed and purified as described (15).

Transactivation Assays-- COS-7 cells were transfected with pSG5 vector containing either CRABP-I or CRABP-II (2 µg), together with DR-5-tk-CAT reporter plasmid (1 µg, see Ref. 23 for details) and pCH110 (0.5 µg). Assays were carried out as described previously (14).

Fluorescence Titrations-- were carried out as described previously (16) and followed either by monitoring the ligand-induced decrease of the fluorescence of the protein (lambda ex = 280 nm, lambda em = 340 nm) (17) or the increase in fluorescence of RA upon binding to CRABP (lambda ex = 360 nm, lambda em = 470 nm) (18). Titration curves were corrected (24) and data fitted to a binding equation (19).

Transfer of RA from CRABP to Unilamellar Vesicles-- Unilamellar vesicles of DOPC (Avanti Polar Lipids) were prepared as described previously (20). Holo-CRABP-I or -II was mixed with vesicles, and RA transfer was monitored by following either the fluorescence of the protein or the fluorescence of RA. Data were fitted to a first order reaction.

Kinetics of Association of RA with CRABP-- Equimolar solutions of CRABP and RA were mixed using a stopped-flow apparatus (HiTech, Salisbury, UK), and complex formation was monitored by following the time-dependent increase in RA fluorescence. Data were fitted to a second order equation.

Transfer of RA from CRABP to RAR-- holo-CRABP was mixed with RAR at varying RAR/CRABP molar ratios in the range of 5-25. Transfer was monitored by the time-dependent decrease in the fluorescence of RA. Data were fitted to a first order equation.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CRABP-II, but Not CRABP-I, Enhances Transcriptional Activation by RA-- To investigate whether either CRABP-I or CRABP-II affects the transcriptional activity of RA, transactivation assays were carried out. A CAT reporter construct containing the response element DR-5, which specifically binds RAR-RXR heterodimers (21), was co-transfected into COS-7 cells together with expression vectors for either CRABP-I or CRABP-II, and the ability of RA to activate transcription of the reporter gene was studied (Fig. 1). Addition of RA induced expression of the reporter in a dose-dependent fashion (Fig. 1, open bars). Overexpression of CRABP-I had little effect on the RA-induced activation (Fig. 1, gray bars). In contrast, expression of CRABP-II markedly stimulated transactivation by RA (Fig. 1, hatched bars) in this system.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of co-expression of CRABP-I and -II on RA-induced transactivation. COS-7 cells were transiently transfected with 2 µg of pSG5 (control), or hCRABP-I or hCRABP-II expression vector, together with 1 µg of DR-5-tk-CAT reporter plasmid. 0.5 µg of the beta -galactosidase expression vector CH110 was used as internal standard. Cells were treated with either Me2SO or the denoted concentrations of RA for a period of 18 h. CAT activity, normalized for beta -galactosidase activity, is presented as -fold induction relative to control cells. Each bar represents the mean ± S.E. from a representative experiment (carried out in triplicate).

The Equilibrium Dissociation Constants of Complexes of CRABP-I and CRABP-II with RA Are Similar-- To examine whether functional differences between CRABP-I and CRABP-II may stem from differences in their RA binding affinity (19), Kd values characterizing the association of RA with CRABP-I and CRABP-II were measured. To this end, the kinetic parameters of the dissociation and the association of complexes of RA with the binding proteins (koff and kon, respectively) were measured. The respective Kd values were obtained by using the relationship Kd = koff/kon.

To withdraw RA from CRABP, unilamellar vesicles of DOPC, serving as a "hydrophobic sink," were used (22). CRABP was pre-complexed with RA, mixed with the vesicles, and movement of the ligand from the protein to the vesicles was followed. RA fluoresces when bound to CRABP-I or II, although it is not fluorescent when associated with lipid vesicles (18). RA transfer from CRABP to vesicles could thus be followed by monitoring the time-dependent decrease in the fluorescent of the ligand. In this assay, because the amount of vesicles used was sufficient to draw >95% of the ligand from the protein, the rate constant of the observed reaction directly reflects the rate constant for dissociation of RA from the protein (koff) (16, 20). Representative traces showing transfer of RA from CRABP-I or CRABP-II to vesicles are shown in Fig. 2, a and b, respectively, and the derived rate constants are listed in Table I. The rate of association of the CRABP·RA complexes was examined by mixing equimolar concentrations of RA and protein and following the time-dependent enhancement of the fluorescence of the ligand upon binding (Fig. 2, c and d). These data were analyzed as described previously (20) to yield kon (Table I). The data indicated that kon for the two proteins are similar and close to the diffusion limit and that koff is 2-fold lower for CRABP-I versus CRABP-II, leading to a 2-fold higher ligand-binding affinity of the former.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Rates of dissociation and association of complexes of RA with CRABP-I or CRABP-II. Rates of dissociation of RA from CRABP-I (a) or CRABP-II (b) were measured as described under "Experimental Procedures." Holo-proteins were mixed with vesicles of DOPC at a molar ratio of 20,000. Transfer was followed by monitoring the time-dependent decrease in the fluorescence of RA. Data were fitted to a first order reaction equation to yield koff. Rates of association of RA with CRABP-I (c) or CRABP-II (d) were monitored following mixing solutions containing equimolar concentrations of the binding protein and RA (final concentration 0.5 µM each). Mixing was carried out using a stopped-flow apparatus in conjunction with the fluorometer. The fluorescence of RA was monitored, and the rate constant for association (kon) was obtained by fitting the data to a second order reaction equation.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Parameters characterizing the interactions of RA with CRABPsa

CRABP-I and CRABP-II Deliver RA to RAR by Different Mechanisms-- It is difficult to see how a 2-fold difference in the Kd of CRABP-I and II may account for their distinct effects on the transcriptional activity of RAR. We thus wondered whether the functional differences between the two proteins may stem from differences in the mechanisms by which they deliver their ligand to RAR. Theoretically, transfer of a ligand from a donor to an acceptor protein may occur by one of two possible mechanisms. One pathway involves initial dissociation of the ligand from the donor into the aqueous phase, followed by association with the acceptor. In this case, the rate-limiting step for the transfer reaction will be the dissociation of the donor-ligand complex, and the rate constant of the reaction will be independent of the nature or the concentration of the acceptor (23). In a second scenario, the ligand will move from the donor to the acceptor by "channeling," i.e. by a process that involves direct protein-protein interactions and that bypasses the aqueous phase. In this case, the rate of the reaction will be limited by the frequency of productive collisions between the donor and the acceptor and will become faster as the acceptor/donor ratio is increased.

Hence, the mechanism by which CRABP "delivers" RA to RAR can be delineated by examining the dependence of the rate constants of ligand transfer between the two proteins on the concentration of the acceptor (RAR). As RA is an efficient fluorophore when bound to either CRABP but not when associated with RAR, transfer could be followed by the time-dependent decrease in RA fluorescence upon mixing of holo-CRABP with apo-RAR. The rate constant for movement of the RA from CRABP-I to RAR was independent of the concentration of the acceptor (Fig. 3a), indicating that movement of RA from CRABP-I to RAR requires prior dissociation of the ligand from CRABP-I. To verify the accuracy of the fluorescence measurements, the rate of transfer was also measured by monitoring movement of 3H-RA from CRABP-I to RAR. Following mixing, separation of the two proteins at different time points was affected by addition of Ni2+ chelating beads which bind the his-tagged RAR but not CRABP. Mixtures were centrifuged, and the remaining CRABP-bound RA was measured by counting. The rate constant thus obtained was essentially identical to that extracted from the fluorescence assays (data not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Dependence of the rate of transfer of RA from CRABP to RAR on the concentration of the acceptor. Holo-CRABP-I (a) or holo-CRABP-II (b) (1 µM) was mixed with RAR at concentrations of 5, 10, 21, or 25 µM. Transfer of RA from the binding protein to the receptor was monitored by measuring the time-dependent decrease in RA fluorescence (lambda ex = 360 nm, lambda em = 470 nm) following mixing of holo-CRABP with RAR. Data were fitted to a first order reaction equation to obtain the reaction rate constants. The apparent half-life (t1/2) of the transfer reactions are shown as a function of the concentration of RAR. Data are presented as mean ± S.E. (n = 3-6), except [RAR] = 21 µM where n = 2.

In contrast with CRABP-I, the pseudo first order rate constant for movement of RA from CRABP-II to RAR (Fig. 3b) strongly depended on the concentration of the acceptor; a 5-fold increase in the concentration of RAR facilitated that rate of transfer of RA from CRABP-II to RAR by 5-fold. This behavior strongly indicates that movement of RA from CRABP-II to RAR is mediated by direct protein-protein interactions between the two proteins.

Overall, the data reveal that while CRABP-I acts as a passive vehicle for RA which binds and releases its ligand in response to shifts in equilibrium conditions, CRABP-II delivers RA to RAR by "channeling" between the two proteins. These observations show further that the interactions between CRABP-II and RAR result in significant facilitation of the formation of the RAR-RA complex and may be the basis for the enhancing effect of CRABP-II on the RAR-mediated transactivation.

The Interactions between CRABP-II and RAR Are Transient-- To further characterize the interactions that mediate transfer of RA between CRABP-II and RAR, we attempted to demonstrate formation of a stable complex between the two proteins. The following methods were used: 1) chemical cross-linking (13), 2) electrophoresis under nondenaturing conditions, 3) fluorescence anisotropy titrations (24, 25), 4) electrophoretic mobility-shift assays, intended to examine whether cognate DNA may stabilize the complex (25). We could not detect complex formation using any of these methods. It thus seems that the interactions of CRABP-II·RAR complex is an unstable intermediate with a short half-life.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Two classes of proteins are believed to be involved in regulating the transcriptional activities of RA: the retinoid nuclear receptors RAR and RXR, and the cellular RA-binding proteins CRABP-I and CRABP-II. The mechanisms of action of retinoid receptors have become increasingly understood in recent years. However, despite the striking level of conservation of CRABP across species, which suggest that they play critical roles in RA action, and although the remarkably different expression profiles of the two CRABP isoforms suggest that they play different roles in RA biology, neither the exact functions of these proteins nor the nature of their distinct roles are clear at present. The current study was thus undertaken to investigate possible functional differences between CRABP-I and CRABP-II.

The data presented in Fig. 1 demonstrate that expression of CRABP-II markedly stimulates the RA-induced transcriptional activity of RAR and that, in contrast, CRABP-I has no effect on this activity. Hence, the two proteins display remarkable functional differences.

It was previously shown that elevated expression of CRABP-I in F9 teratocarcinoma cells inhibits the transcriptional activity of RAR, and it was suggested that CRABP-I directs RA to enzymes that catalyze its degradation (10, 11). In contrast, the data in Fig. 1, in agreement with previous studies carried out using CV-1 cells (26), show that expression of CRABP-I had little effect on RA-induced transactivation in COS-7 cells. It thus seems that the effect of CRABP-I on the transcriptional activity of RAR depends on the particular cell type. It is reasonable to suggest, for example, that CRABP-I inhibits the transcriptional activity of RA only in cells that express RA-metabolizing enzymes that are under its direct regulation. Such enzymes were demonstrated to exist in F9 cells (11). To our knowledge, metabolism of RA in either COS-7 or CV-1 has not been studied in depth.

The Kd values of complexes of RA with CRABP-I and -II were found to differ by only 2-fold (Table I), suggesting that it is unlikely that the functional differences between the two proteins stem from differential ligand-binding affinities. We thus set out to examine whether CRABP-I and -II might deliver their ligand to RAR by different mechanisms. Theoretically, there are two possible pathways by which a ligand can move from a donor to an acceptor protein. Transfer may proceed by dissociation of the ligand from the donor to the aqueous phase, followed by association with the acceptor. In this scheme, the rate of transfer will be limited by the rate of dissociation of the donor-ligand complex. Alternatively, the ligand may transfer from the donor to the acceptor by a process that is mediated by direct protein-protein interactions. In this case, the rate of transfer will depend on the probability of productive collisions between the two proteins and will be faster as the acceptor/donor ratio is increased. Studies of the kinetic patterns of the movement of RA between the binding proteins and RAR (Fig. 3) demonstrated that transfer of RA from CRABP-I to RAR is indicative of a process that requires prior dissociation of the RA·CRABP-I complex (see Fig. 4a). This conclusion is also supported by the observations that the rate constant for dissociation of RA from CRABP-I was similar regardless of whether the acceptor was RAR or lipid vesicles (Table I).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Mechanisms of transfer of RA from CRABPs to RAR. Schematic representations of the suggested pathways by which CRABP-I (a) or CRABP-II (b) deliver RA to RAR.

In contrast with CRABP-I, the pattern of movement of RA from CRABP-II to RAR was characteristic of a process that is mediated by direct interactions between the two proteins (see Fig. 4b). Further, the data showed that these interactions result in a significant facilitation of the delivery of RA to the receptor. Hence, CRABP-II enhances the transcriptional activity of RAR by directly interacting with the receptor, thereby facilitating the formation of the active RAR·RA complex. Interestingly, it was recently reported that ectopic expression of CRABP-II enhances transcriptional activation by RA in mammary carcinoma cell lines (27) and that expression of a CRABP-II antisense construct in SCC25 cells renders these cells less sensitive to RA-mediated inhibition of proliferation (12). No suggestions for the mechanism that may underlie these observations were put forward in these reports, but the results of the present work suggest that these effects were mediated by the CRABPII-dependent facilitation of the formation of holo-RAR. It is also worth noting that it has been reported that the expression of CRABP-II is elevated in cells that synthesize relatively large amounts of RA (5, 28, 29). These observations can be understood, in view of the present findings, to imply that increased physiological needs for RA require both an increase in RA synthesis and an up-regulation of CRABP-II, allowing for rapid delivery of newly synthesized RA to RAR.

Our efforts to demonstrate a stable complex between CRABP-II and RAR failed despite utilization of multiple experimental approaches. It thus seems that the interactions between the two proteins are transient in nature and that the CRABP-II·RAR complex is a short-lived intermediate. Transient interactions that serve to channel ligands between proteins have been previously documented for several enzymes, for example within the purine biosynthetic pathway (30). In these cases, similar to the present study, it was not possible to isolate a stable complex between the proteins involved although it has been established that direct protein-protein interactions indeed occur and play an important role in this particular metabolic pathway. To the best of our knowledge, the present work constitutes the first example for channeling of a small ligand between two proteins for purposes other than movement of a substrate down a metabolic pathway.

    ACKNOWLEDGEMENTS

We thank Anuradha Budhu for measurements of rates of transfer of 3H-RA between CRABP-I and RAR. We are grateful to David Ong, for providing bacterial expression vectors for CRABP-I and CRABP-II, and to Hinrich Gronemeyer and Pierre Chambon, for cDNA for CRABP-I, CRABP-II, and RAR and for the DR5-tk-CAT reporter construct.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA68150 and Grant 5-T32-DK07158 (to D. D.) and by United States Department of Agriculture Grant 89-34115-4498.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Savage Hall, Cornell University, Ithaca, NY 14853. Tel.: 607-255-2490; Fax: 607-255-1033; E-mail: nn14@cornell.edu.

    ABBREVIATIONS

The abbreviations used are: RA, retinoic acid; RAR, retinoic acid receptor; CRABP, cellular retinoic acid-binding protein; RXR, retinoid X receptor; DOPC, dioleylphosphatidychloline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Chambon, P. (1996) FASEB J. 10, 940-954[Abstract]
2. Ong, D. E., Newcomer, M. E., and Chytil, F. (1994) in The Retinoids: Biology, Chemistry and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), 2nd Ed. , pp. 288-317, Raven Press, NY
3. Zheng, W. L., and Ong, D. E. (1998) Biol. Reprod. 58, 963-970[Abstract/Free Full Text]
4. Wardlaw, S., Bucco, R. A., Zheng, W. L., and Ong, D. E. (1997) Biol. Reprod. 56, 125-132[Abstract]
5. Yamamoto, M., Drager, U. C., Ong, D. E., and McCaffery, P. (1998) Eur. J. Biochem. 257, 344-350[Medline] [Order article via Infotrieve]
6. Maden, M. (1994) in Vitamin A in Health and Disease (Blomhoff, R., ed) , pp. 289-322, Marcel Dekker, NY
7. Gorry, P., Lufkin, T., Dierich, A., Rochtte-Egly, C., Decimo, D., Dolle, P., Mark, M., Durand, B., and Chambon, P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9032-9036[Abstract/Free Full Text]
8. Takase, S., Ong, D. E., and Chytil, F. (1986) Arch. Biochem. Biophys. 247, 328-334[CrossRef][Medline] [Order article via Infotrieve]
9. Gaub, M-P., Lutz, Y., Ghyselinck, N. B., Scheuer, I., Pfister, V., Chambon, P., and Rochette-Egly, C. (1998) J. Histochem. Cytochem. 46, 1103-1111[Abstract/Free Full Text]
10. Boylan, J. F., and Gudas, L. J. (1992) J. Biol. Chem. 267, 21486-21491[Abstract/Free Full Text]
11. Boylan, J. F., and Gudas, L. J. (1991) J. Cell Biol. 12, 965-979
12. Vo, H. P., and Crowe, D. L. (1998) Anticancer Res. 18, 217-224[Medline] [Order article via Infotrieve]
13. Kersten, S., Kelleher, D., Chambon, P., Gronemeyer, H., and Noy, N. (1995) Proc. Natl. Acad. Sci. U. S. A. 96, 10014-10017
14. Chen, Z.-P., Iyer, J., Bourguet, W., Held, P., Mioskowski, C., Lebeau, L., Noy, N., Chambon, P., and Gronemeyer, H. (1998) J. Mol. Biol. 275, 55-65[CrossRef][Medline] [Order article via Infotrieve]
15. Jamison, R. S., Newcomer, M. E., and Ong, D. E. (1994) Biochemistry 33, 2873-2879[CrossRef][Medline] [Order article via Infotrieve]
16. Kersten, S., Dawson, M. I., Lewis, B. A., and Noy, N. (1996) Biochemistry 34, 3816-3824
17. Cogan, U., Kopelman, M., Mokady, S., and Shinitzky, M. (1976) Eur. J. Biochem. 65, 71-78[Medline] [Order article via Infotrieve]
18. Fiorella, P. D., Giguere, V., and Napoli, J. L. (1993) J. Biol. Chem. 268, 21545-21552[Abstract/Free Full Text]
19. Norris, A. W., Cheng, L., Giguere, V., Rosenberger, M., and Li, E. (1994) Biochim. Biophys. Acta 1209, 10-18[CrossRef][Medline] [Order article via Infotrieve]
20. Noy, N., and Xu, Z.-J. (1990) Biochemistry 29, 3878-3883[CrossRef][Medline] [Order article via Infotrieve]
21. Mangelsdorf, D. J., Umesono, K., and Evans, M. R. (1994) in The Retinoids: Biology, Chemistry and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), 2nd Ed. , pp. 319-349, Raven Press, NY
22. Chen, Y., Houghton, L. A., Brenna, J. T., and Noy, N. (1996) J. Biol. Chem. 271, 20507-20515[Abstract/Free Full Text]
23. Daniels, C., Noy, N., and Zakim, D. (1985) Biochemistry 24, 3286-3292[CrossRef][Medline] [Order article via Infotrieve]
24. Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , pp. 112-150, Plenum Press, New York
25. Dong, D., and Noy, N. (1998) Biochemistry 37, 10691-10700[CrossRef][Medline] [Order article via Infotrieve]
26. Venepally, P., Reddy, L. G., and Sani, B. P. (1996) Biochemistry 35, 9974-9982[CrossRef][Medline] [Order article via Infotrieve]
27. Jing, Y., Waxman, S., and Mira-y-Lopez, R. (1997) Cancer Res. 57, 1668-1672[Abstract/Free Full Text]
28. Zheng, W. L., Bucco, R. A., Schmitt, M. C, Wardlaw, S. A., and Ong, D. E. (1996) Endocrinology 137, 5028-5035[Abstract]
29. Bucco, R. A., Zheng, W. L., Davis, J. T., Sierra-Rievra, E., Osteen, K. G., Chaudhary, A. K., and Ong, D. E. (1997) Biochemistry 36, 4009-4014[CrossRef][Medline] [Order article via Infotrieve]
30. Rudolph, J., and Stubbe, J. (1995) Biochemistry 34, 2241-2250[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
Mol Hum ReprodHome page
M. Zaitseva, B. J. Vollenhoven, and P. A.W. Rogers
Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium
Mol. Hum. Reprod., August 1, 2007; 13(8): 577 - 585.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. J. Donato, J. H. Suh, and N. Noy
Suppression of Mammary Carcinoma Cell Growth by Retinoic Acid: the Cell Cycle Control Gene Btg2 Is a Direct Target for Retinoic Acid Receptor Signaling
Cancer Res., January 15, 2007; 67(2): 609 - 615.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Tozaki-Saitoh, S. Koizumi, Y. Sato, M. Tsuda, T. Nagao, and K. Inoue
Retinoic Acids Increase P2X2 Receptor Expression through the 5'-Flanking Region of P2rx2 Gene in Rat Phaeochromocytoma PC-12 Cells
Mol. Pharmacol., July 1, 2006; 70(1): 319 - 328.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. J. Donato and N. Noy
Suppression of Mammary Carcinoma Growth by Retinoic Acid: Proapoptotic Genes Are Targets for Retinoic Acid Receptor and Cellular Retinoic Acid-Binding Protein II Signaling
Cancer Res., September 15, 2005; 65(18): 8193 - 8199.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T. Wang and C. Montell
Rhodopsin Formation in Drosophila Is Dependent on the PINTA Retinoid-Binding Protein
J. Neurosci., May 25, 2005; 25(21): 5187 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. A. Arslan, L. I. Gold, K. Mittal, T.-C. Suen, I. Belitskaya-Levy, M.-S. Tang, and P. Toniolo
Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review
Hum. Reprod., April 1, 2005; 20(4): 852 - 863.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X.-H. Li, B. Kakkad, and D. E. Ong
Estrogen Directly Induces Expression of Retinoic Acid Biosynthetic Enzymes, Compartmentalized between the Epithelium and Underlying Stromal Cells in Rat Uterus
Endocrinology, October 1, 2004; 145(10): 4756 - 4762.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. M. Janes, T. A. Ofstad, D. H. Campbell, F. M. Watt, and D. M. Prowse
Transient activation of FOXN1 in keratinocytes induces a transcriptional programme that promotes terminal differentiation: contrasting roles of FOXN1 and Akt
J. Cell Sci., August 15, 2004; 117(18): 4157 - 4168.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S.-K. Kim, J.-I. Yoo, B.-K. Cho, S. J. Hong, Y.-K. Kim, J.-A. Moon, J. H. Kim, Y.-N. Chung, and K.-C. Wang
Elevation of CRABP-I in the Cerebrospinal Fluid of Patients With Moyamoya Disease
Stroke, December 1, 2003; 34(12): 2835 - 2841.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Shaw, M. Elholm, and N. Noy
Retinoic Acid Is a High Affinity Selective Ligand for the Peroxisome Proliferator-activated Receptor {beta}/{delta}
J. Biol. Chem., October 24, 2003; 278(43): 41589 - 41592.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-H. Li and D. E. Ong
Cellular Retinoic Acid-binding Protein II Gene Expression Is Directly Induced by Estrogen, but Not Retinoic Acid, in Rat Uterus
J. Biol. Chem., September 12, 2003; 278(37): 35819 - 35825.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Manor, E. N. Shmidt, A. Budhu, A. Flesken-Nikitin, M. Zgola, R. Page, A. Yu. Nikitin, and N. Noy
Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II
Cancer Res., August 1, 2003; 63(15): 4426 - 4433.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Golovleva, S. Bhattacharya, Z. Wu, N. Shaw, Y. Yang, K. Andrabi, K. A. West, M. S. I. Burstedt, K. Forsman, G. Holmgren, et al.
Disease-causing Mutations in the Cellular Retinaldehyde Binding Protein Tighten and Abolish Ligand Interactions
J. Biol. Chem., March 28, 2003; 278(14): 12397 - 12402.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Despouy, J.-N. Bastie, S. Deshaies, N. Balitrand, A. Mazharian, C. Rochette-Egly, C. Chomienne, and L. Delva
Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II
J. Biol. Chem., February 14, 2003; 278(8): 6355 - 6362.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
N.-S. Tan, N. S. Shaw, N. Vinckenbosch, P. Liu, R. Yasmin, B. Desvergne, W. Wahli, and N. Noy
Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription
Mol. Cell. Biol., July 15, 2002; 22(14): 5114 - 5127.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. S. Budhu and N. Noy
Direct Channeling of Retinoic Acid between Cellular Retinoic Acid-Binding Protein II and Retinoic Acid Receptor Sensitizes Mammary Carcinoma Cells to Retinoic Acid-Induced Growth Arrest
Mol. Cell. Biol., April 15, 2002; 22(8): 2632 - 2641.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
R. Ruhl, C. Plum, M. M. A. Elmazar, and H. Nau
Embryonic Subcellular Distribution of 13-cis- and All-trans-Retinoic Acid Indicates Differential Cytosolic/Nuclear Localization
Toxicol. Sci., September 1, 2001; 63(1): 82 - 89.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Hippo, M. Yashiro, M. Ishii, H. Taniguchi, S. Tsutsumi, K. Hirakawa, T. Kodama, and H. Aburatani
Differential Gene Expression Profiles of Scirrhous Gastric Cancer Cells with High Metastatic Potential to Peritoneum or Lymph Nodes
Cancer Res., February 1, 2001; 61(3): 889 - 895.
[Abstract] [Full Text]


Home page
Protein Sci.Home page
A. Radominska-Pandya, G. Chen, V. M. Samokyszyn, J. M. Little, W. E. Gall, G. Zawada, N. Terrier, J. Magdalou, and P. Czernik
Application of photoaffinity labeling with [3H] all trans- and 9-cis-retinoic acids for characterization of cellular retinoic acid-binding proteins I and II
Protein Sci., January 1, 2001; 10(1): 200 - 211.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
T. Helledie, M. Antonius, R. V. Sørensen, A. V. Hertzel, D. A. Bernlohr, S. Kølvraa, K. Kristiansen, and S. Mandrup
Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm
J. Lipid Res., November 1, 2000; 41(11): 1740 - 1751.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, D.
Right arrow Articles by Noy, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, D.
Right arrow Articles by Noy, N.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.